Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder
- The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD).
- The approval for the treatment comes as a monotherapy or in combination with immunosuppressive therapy.
- Enspryng is the first and only NMOSD treatment administered subcutaneously every four weeks, allowing home-dosing after appropriate training.
- The EU approval follows FDA's nod last August to treat the rare condition, also called Devic's disease, where the immune system damages the spinal cord and the nerves of the eyes.
- Price Action: RHHBY shares are up 0.8% at $46.97 during the premarket session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs European Medicines Agency (EMA) inflammatory diseasesBiotech News Health Care FDA General
